Herantis Pharma Oyj (HRTIS) — Cash Flow-to-Debt Ratio
Herantis Pharma Oyj (HRTIS) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2025, meaning its operating cash flow of €-3.39 Million could theoretically repay -1% of its total liabilities (€3.36 Million) in one year. See Herantis Pharma Oyj (HRTIS) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Herantis Pharma Oyj Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Herantis Pharma Oyj across 13 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Herantis Pharma Oyj.
Annual Cash Flow-to-Debt Ratio for Herantis Pharma Oyj (2012–2024)
Year-by-year debt coverage analysis for Herantis Pharma Oyj. Check HRTIS operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.33x | €-6.54 Million | €2.81 Million | ▼ -1.3% |
| 2023 | -2.30x | €-4.64 Million | €2.02 Million | ▼ -61.5% |
| 2022 | -1.42x | €-8.94 Million | €6.29 Million | ▲ +8.9% |
| 2021 | -1.56x | €-9.93 Million | €6.36 Million | ▼ -61.1% |
| 2020 | -0.97x | €-8.56 Million | €8.83 Million | ▼ -50.0% |
| 2019 | -0.65x | €-5.96 Million | €9.22 Million | ▼ -25.3% |
| 2018 | -0.52x | €-3.73 Million | €7.24 Million | ▼ -48.5% |
| 2017 | -0.35x | €-2.60 Million | €7.48 Million | ▲ +1.2% |
| 2016 | -0.35x | €-3.04 Million | €8.63 Million | ▲ +61.5% |
| 2015 | -0.91x | €-7.40 Million | €8.09 Million | ▼ -63.1% |
| 2014 | -0.56x | €-4.36 Million | €7.77 Million | ▼ -530.5% |
| 2013 | -0.09x | €-224.21K | €2.52 Million | ▲ +63.1% |
| 2012 | -0.24x | €-533.42K | €2.21 Million | — |